Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

(2022) Robbie G. Majzner et al.   NATURE

Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells

(2022) Talar Tokatlian et al.   Journal for ImmunoTherapy of Cancer

Enhanced safety and efficacy of protease-regulated CAR-T cell receptors

(2022) Louai Labanieh et al.   CELL

Modular design of synthetic receptors for programmed gene regulation in cell therapies

(2022) Iowis Zhu et al.   CELL

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

(2022) Changsong Qi et al.   NATURE MEDICINE

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion

(2022) Leila Amini et al.   Nature Reviews Clinical Oncology

Human organs-on-chips for disease modelling, drug development and personalized medicine

(2022) Donald E. Ingber   NATURE REVIEWS GENETICS

A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo

(2022) Mark L. Sandberg et al.   Science Translational Medicine

Size-dependent activation of CAR-T cells

(2022) Qian Xiao et al.   Science Immunology

High-performance multiplex drug-gated CAR circuits

(2022) Hui-Shan Li et al.   CANCER CELL

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide

(2021) Max Jan et al.   Science Translational Medicine

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

(2021) Babak Moghimi et al.   Nature Communications

Utility of Safety Switch to Abrogate CD19.CAR T Cell-Associated Neurotoxicity

(2021) Matthew C Foster et al.   BLOOD

Immunogenicity of CAR T cells in cancer therapy

(2021) Dimitrios L. Wagner et al.   Nature Reviews Clinical Oncology

T cell circuits that sense antigen density with an ultrasensitive threshold

(2021) Rogelio A. Hernandez-Lopez et al.   SCIENCE

Phenotypic diversity and metabolic specialization of renal endothelial cells

(2021) Sébastien J. Dumas et al.   Nature Reviews Nephrology

Targeting loss of heterozygosity for cancer-specific immunotherapy

(2021) Michael S. Hwang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

(2021) Evan W. Weber et al.   SCIENCE

SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models

(2021) Axel Hyrenius-Wittsten et al.   Science Translational Medicine

SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma

(2021) Joseph H. Choe et al.   Science Translational Medicine

IFNg is Critical for CAR T Cell Mediated Myeloid Activation and Induction of Endogenous Immunity

(2021) Darya Alizadeh et al.   Cancer Discovery

Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients

(2021) Yajun Zhang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

(2021) Nicholas A. Vitanza et al.   NATURE MEDICINE

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab

(2021) Prasad S Adusumilli et al.   Cancer Discovery

CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function

(2021) Ali Can Sahillioglu et al.   Cancer Immunology Research

Titratable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors

(2021) Bettina Kotter et al.   Cancers

Control of the activity of CAR-T cells within tumours via focused ultrasound

(2021) Yiqian Wu et al.   Nature Biomedical Engineering

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

(2021) Sabine Heitzeneder et al.   CANCER CELL

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

(2021) Oliver Van Oekelen et al.   NATURE MEDICINE

Tunable control of CAR T cell activity through tetracycline mediated disruption of protein–protein interaction

(2021) Alastair Hotblack et al.   Scientific Reports

Engineering light-controllable CAR T cells for cancer immunotherapy

(2020) Ziliang Huang et al.   Science Advances

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

(2020) Jennifer M. Logue et al.   HAEMATOLOGICA

Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors

(2020) Johanna Theruvath et al.   NATURE MEDICINE

Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

(2020) Laura K. Donovan et al.   NATURE MEDICINE

Tuning the Antigen Density Requirement for CAR T-cell Activity

(2020) Robbie G. Majzner et al.   Cancer Discovery

GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab

(2020) Daiki Kato et al.   eLife

Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial

(2020) Yang Liu et al.   CYTOTHERAPY

Oxygen battle in the gut: Hypoxia and hypoxia-inducible factors in metabolic and inflammatory responses in the intestine

(2020) Rashi Singhal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo

(2020) Sarah A. Richman et al.   MOLECULAR THERAPY

A conformation-specific ON-switch for controlling CAR T cells with an orally available drug

(2020) Charlotte U. Zajc et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab®

(2020) Justyna Jureczek et al.   OncoTargets and Therapy

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma

(2020) Meenakshi Hegde et al.   Nature Communications

A rational mouse model to detect on-target, off-tumor CAR T cell toxicity

(2020) Mauro Castellarin et al.   JCI Insight

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.

(2020) M.-L. Schubert et al.   ANNALS OF ONCOLOGY

Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: First report of FAPME, a phase I clinical trial

(2020) S. Hiltbrunner et al.   ANNALS OF ONCOLOGY

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

(2020) Kevin R. Parker et al.   CELL

Engineered T cells directed at tumors with defined allelic loss

(2020) Agnes E. Hamburger et al.   MOLECULAR IMMUNOLOGY

Designed protein logic to target cells with precise combinations of surface antigens

(2020) Marc J. Lajoie et al.   SCIENCE

Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function

(2020) Benjamin Salzer et al.   Nature Communications

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy

(2020) Xin Cui et al.   eLife

Revisiting the Warburg effect: historical dogma versus current understanding

(2020) Peter Vaupel et al.   JOURNAL OF PHYSIOLOGY-LONDON

Precise T cell recognition programs designed by transcriptionally linking multiple receptors

(2020) Jasper Z. Williams et al.   SCIENCE

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

(2020) Karin Straathof et al.   Science Translational Medicine

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

(2019) Mohamed-Reda Benmebarek et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting

(2019) Shivani Srivastava et al.   CANCER CELL

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells

(2019) Hongwei Du et al.   CANCER CELL

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer

(2019) Leticia De Mattos-Arruda et al.   Cell Reports

Modulation of chimeric antigen receptor surface expression by a small molecule switch

(2019) Alexandre Juillerat et al.   BMC BIOTECHNOLOGY

Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers

(2019) Andrew R. Haas et al.   MOLECULAR THERAPY

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

(2019) Katrin Mestermann et al.   Science Translational Medicine

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells

(2019) Stefanie Koristka et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

(2019) Olli Dufva et al.   BLOOD

Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma

(2019) Liang-qing Dong et al.   JOURNAL OF HEPATOLOGY

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

(2018) Jang Hwan Cho et al.   CELL

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

(2018) Gregory L. Beatty et al.   GASTROENTEROLOGY

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

(2018) Shivani Srivastava et al.   JOURNAL OF IMMUNOLOGY

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

(2018) John A. Thompson   Journal of the National Comprehensive Cancer Network

A Rapamycin-Activated Caspase 9-Based Suicide Gene

(2018) Maria Stavrou et al.   MOLECULAR THERAPY

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas

(2018) Christopher W. Mount et al.   NATURE MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanogenetics for the remote and noninvasive control of cancer immunotherapy

(2018) Yijia Pan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity

(2018) A. J. Davenport et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment

(2018) Sujita Sukumaran et al.   Cancer Discovery

Neurotoxicity Associated with a High-Affinity GD2 CAR—Letter

(2018) Robbie G. Majzner et al.   Cancer Immunology Research

Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells

(2018) Anandani Nellan et al.   Journal for ImmunoTherapy of Cancer

Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy

(2018) Erhao Zhang et al.   Journal of Hematology & Oncology

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+and CD30−Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions

(2018) Lee K. Hong et al.   Cancer Immunology Research

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

(2018) Judith Feucht et al.   NATURE MEDICINE

Two-Dimensional Regulation of CAR-T Therapy with Orthogonal Switches

(2018) MyLinh T. Duong et al.   Molecular Therapy-Oncolytics

Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

(2017) Kai-chao Feng et al.   Journal of Hematology & Oncology

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

Masked Chimeric Antigen Receptor for Tumor-Specific Activation

(2017) Xiaolu Han et al.   MOLECULAR THERAPY

Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains

(2017) Leah Alabanza et al.   MOLECULAR THERAPY

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models

(2017) Melinda Mata et al.   Cancer Discovery

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells

(2017) Nicola Mitwasi et al.   Oncotarget

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”

(2017) Anja Feldmann et al.   Oncotarget

An oxygen sensitive self-decision making engineered CAR T-cell

(2017) Alexandre Juillerat et al.   Scientific Reports

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

(2017) Kaichao Feng et al.   Protein & Cell

High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model

(2017) Sarah A. Richman et al.   Cancer Immunology Research

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer

(2017) Julia Tchou et al.   Cancer Immunology Research

A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform

(2017) Susann Albert et al.   OncoImmunology

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity

(2017) Spencer Park et al.   Scientific Reports

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

(2016) C. H. J. Lamers et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors

(2016) Leonardo Morsut et al.   CELL

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

(2016) Kole T. Roybal et al.   CELL

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia

(2016) Paulina J. Paszkiewicz et al.   JOURNAL OF CLINICAL INVESTIGATION

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

(2016) Meenakshi Hegde et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy

(2016) Jenessa B Smith et al.   MOLECULAR THERAPY

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

(2016) Tessa Gargett et al.   MOLECULAR THERAPY

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier

(2016) Roberto Villaseñor et al.   Scientific Reports

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

(2015) X. Liu et al.   CANCER RESEARCH

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

(2015) H. G. Caruso et al.   CANCER RESEARCH

Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

(2015) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

(2015) C.-Y. Wu et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Tissue-based map of the human proteome

(2015) M. Uhlen et al.   SCIENCE

Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.

(2015) Nabil Ahmed et al.   Journal for ImmunoTherapy of Cancer

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

(2014) B. Philip et al.   BLOOD

An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease

(2014) Moniek A. de Witte et al.   JOURNAL OF IMMUNOLOGY

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

(2013) Thomas C. Wehler et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

(2013) G. L. Beatty et al.   Cancer Immunology Research

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

(2011) X. Wang et al.   BLOOD

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

(2011) M. Chmielewski et al.   CANCER RESEARCH

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment

(2011) Ling Zhang et al.   MOLECULAR THERAPY

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Towards a knowledge-based Human Protein Atlas

(2010) Mathias Uhlen et al.   NATURE BIOTECHNOLOGY

Switch from perforin-expressing to perforin-deficient CD8+T cells accounts for two distinct types of effector cytotoxic T lymphocytesin vivo

(2009) Avihai Meiraz et al.   IMMUNOLOGY

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

(2008) K. Porkka et al.   BLOOD

EGF receptor variant III as a target antigen for tumor immunotherapy

(2008) Gordon Li et al.   Expert Review of Vaccines

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE